Literature DB >> 10476522

Antihistamines in the management of allergic pruritus in dogs and cats.

D W Scott1, W H Miller.   

Abstract

Antihistamines clearly have a place in the management of pruritus in the atopic dog and cat and, in this paper, important aspects of pharmacology and pharmacokinetics, adverse effects and precautions, and clinical use of these compounds are reviewed. Successful use of antihistamines is dependent on, among other considerations, the adherence to recommended doses and frequencies of administration, the recognition and control of concurrent and secondary factors, the willingness to try several different compounds, and the realisation that these agents are best employed in a preventive fashion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10476522     DOI: 10.1111/j.1748-5827.1999.tb03099.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  4 in total

1.  Treatment of canine atopic dermatitis with zafirlukast, a leukotriene-receptor antagonist: a single-blinded, placebo-controlled study.

Authors:  David A Senter; Danny W Scott; William H Miller
Journal:  Can Vet J       Date:  2002-03       Impact factor: 1.008

2.  An open clinical trial on the efficacy of cetirizine hydrochloride in the management of allergic pruritus in cats.

Authors:  Joya S Griffin; Danny W Scott; William H Miller; Michelle M Tranchina
Journal:  Can Vet J       Date:  2012-01       Impact factor: 1.008

3.  Treatment of canine atopic dermatitis with cetirizine, a second generation antihistamine: a single-blinded, placebo-controlled study.

Authors:  Christopher P Cook; Danny W Scott; William H Miller; J Edward Kirker; Shaun M Cobb
Journal:  Can Vet J       Date:  2004-05       Impact factor: 1.008

4.  Epidemiological evaluation of cat health at a first-response animal shelter in Fukushima, following the Great East Japan Earthquakes of 2011.

Authors:  Aki Tanaka; Philip H Kass; Beatriz Martinez-Lopez; Shinichi Hayama
Journal:  PLoS One       Date:  2017-03-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.